ADA and Immunodeficiency: The clinical value of PEGylation was first shown with PEG-adenosine deaminase (PEG-ADA, Adagen®; Enzon Pharmaceuticals) [25], which has been used since 1990 as replacement therapy for immune deficiency due to inherited ADA deficiency.